Dr. Parthasarathi Das
| ||||||||||||||||||||||||||
| Medicinal Chemistry Division CSIR - Indian Institute of Integrative Medicine,Canal Road, Jammu – 180001 Email: partha@iiim.ac.in http://www.iiim.res.in/People/CV/cv_parthasarathi.php https://www.researchgate.net/profile/Parthasarathi_Das2  | ||||||||||||||||||||||||||
  Positions Held | ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
Awards and Fellowships
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
Principal Scientist Dr. Parthasarathi Das, Department of Medicinal Chemistry CSIR-Indian Institute of Integrative Medicine-Jammu, who has given us interesting tips of his chemical life, and valuable advices to the future extraordinary chemists.
Dr. Parthasarathi Das
CSIR-Indian Institute of Integrative Medicine(IIIM) - Jammu
Research fields: Organic Synthesis, Medicinal Chemistry.
Current Area of Research: Medicinal Chemistry, developments of new synthetic methodology and synthesis of biologically active natural products.
Publications: (1) Copper-catalyzed sequential N-arylation of C-amino-NH-azoles. D. Nageswar Rao, Sk. Rasheed, Ram A Vishwakarma and Parthasarathi Das Chem. Commun 2014, 50, 12911; (2) Direct C-2 arylation of 7-azaindoles:Chemoselective access to multiarylated derivatives. Prakash Kannaboina, K. Anilkumar, S. Aravinda, Ram A. Vishwakarma and Parthasarathi Das. Org. Lett. 2013, 15, 5718.
* The most attractive part in the chemistry:
Common to both life and materials sciences
* How do you get inspiration for new research:
Exploring things that nobody previously achieved
* Why choose Chemistry as your career:
It is easiest way to bring something new to this world
* Advice for junior researchers:
Never give up and be confident in what you do
Common to both life and materials sciences
* How do you get inspiration for new research:
Exploring things that nobody previously achieved
* Why choose Chemistry as your career:
It is easiest way to bring something new to this world
* Advice for junior researchers:
Never give up and be confident in what you do
Research Area
Catalysis
Our research is focused on the discovery of new catalytic, systems for organic synthesis that utilize the power of transition metal catalysts. Our goal is to enable greater efficiency and novel bond constructions in the synthesis of medicinally important heteroaromatics, with applications that extend to natural product synthesis, drug discovery and process chemistry. The development of these methods also provides a platform for mechanistic investigations, which will enable insight into questions of fundamental reactivity and catalyst design.
Total Synthesis
While complex architecture and dense functionality draw our attention to select natural products, with interesting biological activities. Pharmaceutical companies waning interest in natural products reflects the difficulties and costs associated with their synthesis and subsequent structure-activity relationship (SAR) studies. This offers academics the opportunity to develop novel chemical strategies in the context of various therapeutic areas.
Medicinal Chemistry
Infections caused by Gram negative bacteria constitute a major unmet medical need, particularly in the hospital setting, where Gram negative pathogens account for 61% of the infections. Gram-negative bacteria possess an additional outer membrane decorated with lipopolysaccharide (LPS). LPS is composed of three distinct units. The outermost unit is the O-antigen, which is a glycan polymer. This is linked to a sugar-containing core domain which is appended to the membrane anchoring group, lipid A (endotoxin). This outer membrane provides a substantial protective barrier, and Gram-negative bacteria lacking lipid A are either not viable or are highly susceptible to a range of anti-infective drugs, suggesting that enzymes involved in lipid A production could represent new drug targets. Nine unique enzymes catalyze the synthesis of lipid A and UDP-3-O-(R-3-hydroxymyristol)-N-acetylglucosamine deacetylase (LpxC) is a cytosolic zinc−metalloamidase responsible for carrying out the second biosynthetic step. The essential role LpxC plays in the biosynthesis of lipid A, coupled with a lack of homology with mammalian proteins, has catalyzed efforts to identify small molecule LpxC inhibitors for the treatment of serious Gram-negative infections.
| Publications |
|
Parthasarathi Das, Scientist, Indian Institute of Integrative Medicine (CSIR)
Parthasarathi Das received his MSc degree from Burdwan university. He then moved to National Chemical laboratory, Pune to pursue his doctoral studies where he received his PhD in 1998 under the supervision of Dr. Ganesh Pandey. He did postdoctoral work at the RWTH-Aachen, Germany (Prof. H-J Gais), Tohoku University, Japan (Prof. Masahiro Hirama) and Harvard University, USA (Prof. Yoshito Kishi). In 2003 he moved to India to join Discovery Research of Dr. Reddy’s Laboratories Ltd. and worked in discovery chemistry with research focus in various therapeutic areas e.g. oncology, metabolic disorder and antibacterial. In 2011 he moved to Indian Institute of Integrative Medicine (CSIR), a premier research laboratory focused on drug discovery and natural products research. His current research interests include medicinal chemistry, development of new synthetic methodology and synthesis of biologically active natural products. He serves on the editorial board of the journals; The Scientific World Journal-Organic Chemistry and Journal of Pharmaceutics.
|  |
///////
I really like this amazing post.
ReplyDeleteBuy tan brown eutylone